ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hospital

2016 ACR Distinguished Fellows Award Winners Discuss Early Career Contributions to Rheumatology

  |  

For they’re some very good fellows … no, seriously. They are this year’s recipients of the ACR Distinguished Fellows Awards. The Rheumatologist spoke with them about their burgeoning contributions to Advancing Rheumatology! ACR Distinguished Fellow Awards Eric Allenspach, MD, PhD Acting Assistant Professor, Seattle Children’s Hospital, Seattle Background: Dr. Allenspach seeks to understand the genetic basis…

Psoriatic Arthritis Linked to Increased Heart Disease Risk

Carolyn Crist  |  

(Reuters Health)—Arthritis that accompanies the skin condition psoriasis may also come with a higher risk of heart problems, according to a Hong Kong study. In particular, patients with psoriatic arthritis may have a three- to four-fold higher prevalence of coronary atherosclerosis. Clinicians need to identify patients with high cardiovascular (CV) risk so they can provide…

Pulse Therapy & Lupus Nephritis: A 40-Year History, 1976–2016

Morton Scheinberg, MD, PhD  |  

Corticosteroids still represent the mainstay of treatment of patients with active disease. They have been used for more than 60 years, and although prolonged use is associated with organ damage, they have been shown to be lifesaving in various phases of the history of the disease. History of Use First introduced in the late 1960s…

Stronger Malpractice Laws May Not Prevent Surgical Complications

Lisa Rapaport  |  

(Reuters Health)—More aggressive malpractice climates don’t necessarily protect patients from surgical complications, a new study suggests. Supporters of medical malpractice laws that make it easier for patients to sue doctors say these protections are necessary to improve care. But in the current study, the risk of litigation didn’t translate into better outcomes, said study leader…

Pfizer Announces Medicare Reimbursement for Inflectra (infliximab-dyyb), the First Biosimilar Monoclonal Antibody Available in the United States

Pfizer  |  

On Jan. 6, Pfizer Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has included payment information for INFLECTRA (infliximab-dyyb), a biosimilar to REMICADE (infliximab), in its January Average Selling Price (ASP) pricing file. This pricing took effect as of January 1, 2017. Additional claims processing information is listed in the MLN Matters…

Insurance Subcommittee to the Rescue

  |  

Concerned about reimbursement for specialty drugs? Wondering if your patient can continue on a prescribed medication despite formulary changes? Unsure how to request a tier exception? No need to face these issues alone. The ACR has a resource that can assist with questions regarding coverage and payment policies for private insurers and Medicare. That resource…